DMS 0947 Exploratory Study of the Modulation of the Immune System by Vascular Endothelial Growth Factor (VEGF) Blockade in Patients With Glioblastoma Multiforme (GBM)

Trial Profile

DMS 0947 Exploratory Study of the Modulation of the Immune System by Vascular Endothelial Growth Factor (VEGF) Blockade in Patients With Glioblastoma Multiforme (GBM)

Active, no longer recruiting
Phase of Trial: Phase 0

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Temozolomide
  • Indications Glioblastoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 18 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.
    • 02 Mar 2016 Planned End Date changed from 1 Jan 2016 to 1 Jul 2016, as reported by ClinicalTrials.gov.
    • 21 Apr 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top